Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 1/2017

01-01-2017 | Oncology

Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer

Authors: Maria Lee, Hyunjong Lee, Gi Jeong Cheon, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh-Hyun Park, Yong Sang Song

Published in: European Radiology | Issue 1/2017

Login to get access

Abstract

Objectives

To investigate the prognostic value of intratumoral FDG uptake heterogeneity (IFH) derived from PET/CT in patients with epithelial ovarian cancer (EOC).

Methods

We retrospectively reviewed patients with pathologically proven epithelial ovarian cancer who underwent preoperative 18F-FDG PET/CT scans. PET/CT parameters such as maximum and average standardized uptake values (SUVmax and SUVavg), sum of all metabolic tumour volume (MTV), cumulative total lesion glycolysis (TLG) and IFH were assessed. Regression analyses were used to identify clinicopathological and imaging variables associated with disease-free survival (DFS).

Results

Clinicopathological data were reviewed for 61 eligible patients. The median duration of DFS was 13 months (range, 6–26 months), and 18 (29.5 %) patients experienced recurrence. High IFH values were associated with tumour recurrence (P = 0.005, hazard ratio 4.504, 95 % CI 1.572–12.902). The Kaplan-Meier survival graphs showed that DFS significantly differed in groups categorized based on IFH (P = 0.002, log-rank test). Moreover, there were significant differences in DFS (P = 0.009) and IFH (P = 0.040) between patients with and without recurrence.

Conclusions

Preoperative IFH measured by 18F-FDG PET/CT was significantly associated with EOC recurrence. FDG-based heterogeneity could be a useful and potential predicator of EOC recurrence before treatment.

Key Points

• Preoperative IFH was significantly associated with recurrence of EOC
• Disease-free survival significantly differed in groups categorized by IFH
• FDG-based heterogeneity could be a potential predicator of EOC recurrence before treatment
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMed
2.
Angioli R, Capriglione S, Aloisi A et al (2014) Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol 35:7009–7015CrossRefPubMed
3.
Harter P, Muallem ZM, Buhrmann C et al (2011) Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 121:615–619CrossRefPubMed
4.
Chang SJ, Bristow RE (2012) Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. Gynecol Oncol 125:483–492CrossRefPubMed
5.
Braicu EI, Fotopoulou C, Van Gorp T et al (2013) Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol 128:245–251CrossRefPubMed
6.
Chi DS, Bristow RE, Armstrong DK, Karlan BY (2011) Is the easier way ever the better way? J Clin Oncol 29:4073–4075CrossRefPubMed
7.
Pak K, Cheon GJ, Nam HY et al (2014) Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med 55:884–890CrossRefPubMed
8.
Tixier F, Le Rest CC, Hatt M et al (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52:369–378CrossRefPubMedPubMedCentral
9.
El Naqa I, Grigsby P, Apte A et al (2009) Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recogn 42:1162–1171CrossRef
10.
Cook GJ, Yip C, Siddique M et al (2013) Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med 54:19–26CrossRefPubMed
11.
Kidd EA, Grigsby PW (2008) Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res 14:5236–5241CrossRefPubMed
12.
Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A (2011) Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging 38:987–991CrossRefPubMed
13.
Pugachev A, Ruan S, Carlin S et al (2005) Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 62:545–553CrossRefPubMed
14.
Francis RJ, Byrne MJ, van der Schaaf AA et al (2007) Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 48:1449–1458CrossRefPubMed
15.
Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA (2010) Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 67:311–317
16.
Bundschuh RA, Dinges J, Neumann L et al (2014) Textural parameters of tumor heterogeneity in 18F-FDG PET/CT for therapy response assessment and prognosis in patients with locally advanced rectal cancer. J Nucl Med 55:891–897CrossRefPubMed
17.
18.
Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36CrossRefPubMed
19.
Harries M, Gore M (2002) Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 3:529–536CrossRefPubMed
20.
Sorensen M, Horsman MR, Cumming P, Munk OL, Keiding S (2005) Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors. Int J Radiat Oncol Biol Phys 62:854–861CrossRefPubMed
21.
Avril N, Menzel M, Dose J et al (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42:9–16PubMed
22.
Zasadny KR, Tatsumi M, Wahl RL (2003) FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 30:274–280CrossRefPubMed
23.
Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K (2002) Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 26:185–190CrossRefPubMed
24.
Zhao S, Kuge Y, Mochizuki T et al (2005) Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 46:675–682PubMed
25.
van Baardwijk A, Bosmans G, van Suylen RJ et al (2008) Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol 87:55–58CrossRefPubMed
26.
Arriagada R, Le Chevalier T, Quoix E et al (1991) ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 20:1183–1190CrossRefPubMed
27.
Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367PubMed
28.
Bradley J, Thorstad WL, Mutic S et al (2004) Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59:78–86CrossRefPubMed
29.
Paulino AC, Johnstone PA (2004) FDG-PET in radiotherapy treatment planning: Pandora's box? Int J Radiat Oncol Biol Phys 59:4–5CrossRefPubMed
30.
Yang Z, Sun Y, Zhang Y et al (2013) Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo? Clin Breast Cancer 13:359–363CrossRefPubMed
31.
Tateishi U, Terauchi T, Akashi-Tanaka S et al (2012) Comparative study of the value of dual tracer PET/CT in evaluating breast cancer. Cancer Sci 103:1701–1707CrossRefPubMed
Metadata
Title
Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer
Authors
Maria Lee
Hyunjong Lee
Gi Jeong Cheon
Hee Seung Kim
Hyun Hoon Chung
Jae-Weon Kim
Noh-Hyun Park
Yong Sang Song
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 1/2017
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-016-4368-5

Other articles of this Issue 1/2017

European Radiology 1/2017 Go to the issue

Ultrasound

Comparison of diagnostic yield of core-needle and fine-needle aspiration biopsies of thyroid lesions: Systematic review and meta-analysis

Hepatobiliary-Pancreas

Pancreatic MRI for the surveillance of cystic neoplasms: comparison of a short with a comprehensive imaging protocol

Chest

Use of intravoxel incoherent motion diffusion-weighted MR imaging for assessment of treatment response to invasive fungal infection in the lung

Interventional

In vivo effects of bupivacaine and gadobutrol on the intervertebral disc following discoblock and discography: a histological analysis

Computer Applications

Development of an IHE MRRT-compliant open-source web-based reporting platform

Magnetic Resonance

Time-resolved magnetic resonance angiography (MRA) at 3.0 Tesla for evaluation of hemodynamic characteristics of vascular malformations: description of distinct subgroups